1. What is the primary reason an HIV patient should be started on a boosted protease inhibitor regimen?

2. Both the Department of Health and Human Services (DHHS) and the International Antiviral Society–USA (IAS-USA) include all 3 integrase inhibitors (dolutegravir, elvitegravir/cobicistat, raltegravir) as part of their recommended regimens for initial therapy. What is the primary difference between the 2016 DHHS and IAS-USA guidelines with regard to additional options?

3. Which antiretroviral agent has been associated with the most long-term renal and bone toxicity?

4. JP is a 53-year-old man recently diagnosed with HIV infection. His baseline HIV RNA is 125,000 copies/mL and his CD4 cell count is 110 cells/mm3. His HIV genotype is wild type. He also has hepatitis B infection, with an HBV viral load of 1,200,000 copies/mL. He is HLA-B*5701 positive and his creatinine clearance is 60 mL/min. He is eager to start antiretroviral therapy but admits to having a lot of social stress in his life right now. Which of the following regimens would be most appropriate for this patient?

« Return to Activity